Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

External-beam-based partial breast irradiation

Silvia C Formenti1

  • 1Department of Radiation Oncology, New York University School of Medicine, New York, NY 10016, USA. silvia.formenti@nyumc.org

Nature Clinical Practice. Oncology
|May 31, 2007
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining Optimal Fractionation of Neoadjuvant Radiation in Low-Risk, Early-Stage Breast Cancer-Randomized SIGNAL Clinical Trial.

Cancers·2026
Same author

Radiation Oncology-Biology Integration Network: Bridging the Gap between Biological Research and Clinical Practice.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Rewriting the radiation playbook: NSABP B-51 and the rise of pathologic precision.

NPJ breast cancer·2025
Same author

Facts and Hopes in Radioimmunotherapy for Localized Stages of Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR<sup>+</sup>HER2<sup>-</sup> breast cancer via CX3CR1<sup>+</sup> macrophages.

Nature cancer·2025
Same author

IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR<sup>+</sup>HER2<sup>-</sup> breast cancer via CX3CR1<sup>+</sup> macrophages.

Nature cancer·2025